- Home
- JZXN vs FBLG Comparison
JZXN vs FBLG Comparison
Compare JZXN & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- FBLG
- Stock Information
- Founded
- JZXN 2019
- FBLG 2021
- Country
- JZXN China
- FBLG United States
- Employees
- JZXN N/A
- FBLG N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- FBLG
- Sector
- JZXN Consumer Discretionary
- FBLG
- Exchange
- JZXN Nasdaq
- FBLG NYSE
- Market Cap
- JZXN 45.5M
- FBLG 37.1M
- IPO Year
- JZXN 2021
- FBLG 2024
- Fundamental
- Price
- JZXN $3.74
- FBLG $0.86
- Analyst Decision
- JZXN
- FBLG Strong Buy
- Analyst Count
- JZXN 0
- FBLG 4
- Target Price
- JZXN N/A
- FBLG $13.00
- AVG Volume (30 Days)
- JZXN 33.0K
- FBLG 143.6K
- Earning Date
- JZXN 05-19-2025
- FBLG 05-13-2025
- Dividend Yield
- JZXN N/A
- FBLG N/A
- EPS Growth
- JZXN N/A
- FBLG N/A
- EPS
- JZXN N/A
- FBLG N/A
- Revenue
- JZXN $1,400,139.00
- FBLG N/A
- Revenue This Year
- JZXN N/A
- FBLG N/A
- Revenue Next Year
- JZXN N/A
- FBLG $235.70
- P/E Ratio
- JZXN N/A
- FBLG N/A
- Revenue Growth
- JZXN N/A
- FBLG N/A
- 52 Week Low
- JZXN $1.00
- FBLG $0.90
- 52 Week High
- JZXN $67.60
- FBLG $13.59
- Technical
- Relative Strength Index (RSI)
- JZXN 47.54
- FBLG 35.97
- Support Level
- JZXN $3.00
- FBLG $0.90
- Resistance Level
- JZXN $5.30
- FBLG $1.16
- Average True Range (ATR)
- JZXN 0.75
- FBLG 0.08
- MACD
- JZXN -0.12
- FBLG 0.01
- Stochastic Oscillator
- JZXN 50.00
- FBLG 12.08
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.